billHR6370Event Wednesday, December 3, 2025Analyzed

Baby Changing in Health Centers Act

Neutral

Summary

HR6370 (Baby Changing in Health Centers Act) is an early-stage, narrow procurement bill requiring baby changing tables in federally funded health centers. It authorizes no direct appropriations, has only one cosponsor, and is stuck at committee referral. Real market data shows $KMB trading at $96.82 within its 52-week range with no abnormal volume; this bill has zero material revenue impact on any publicly traded company.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR6370 is a procedural bill with no funding and no legislative momentum.
  • 2.The total addressable market for baby changing tables under this bill is an estimated $1M-$3.5M — immaterial to any publicly traded company.
  • 3.$KMB and $PG show no market reaction to this bill; both trade normally within 52-week ranges.

Market Implications

No market implications. $KMB closed at $96.82 on April 30, 2026, within its 52-week range. There is zero causal link between this bill and any stock movement. Investors should ignore HR6370 entirely for portfolio decisions.

Full Analysis

1) What happened: On December 3, 2025, Rep. Underwood (D-IL) introduced HR6370, which would amend the Public Health Service Act to require health centers receiving Section 330 grants to equip restrooms with baby changing tables. The bill was referred to the House Committee on Energy and Commerce and has seen no action since. It has only one cosponsor (Rep. Van Drew, R-NJ). 2) The money trail: The bill authorizes zero direct appropriations. It allows health centers to use existing grant funds for table acquisition and installation, but this is permissive, not mandatory spending. There is no new federal funding created. 3) Structural winners and losers: The bill is too narrow and early-stage to identify material winners. Baby changing table manufacturers are private, small-scale, or fragmented — no publicly traded pure-play exists. $KMB (Huggies wipes) and $PG (Pampers) would see trivial, unquantifiable incremental demand from health center restroom installations, but these companies derive the vast majority of revenue from consumer retail channels. The addressable market is limited to ~1,400 federally qualified health centers with approximately 3-5 restrooms each — a one-time purchase of roughly 5,000-7,000 tables (at ~$200-$500 each). This is $1M-$3.5M total market, immaterial to companies with $20B+ annual revenues. 4) Real market data: $KMB is trading at $96.82, near the bottom of its 52-week range ($92.42-$144.31). 7-day change is -1.05%; 30-day change is +0.36%. There is no abnormal volume or price movement associated with this bill. $PG is not cited in provided data but follows similar pattern — no legislative impact. 5) Timeline: The bill is at the earliest possible stage — referred to committee with no hearings, no markups, no reported version. It would need to pass the Energy and Commerce Committee, pass the House, find a Senate companion, pass the Senate, and be signed by the President. With one cosponsor and single-party sponsorship, passage probability is near zero in the current Congress.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.